Introduction of the anti-TNFα therapies infliximab, etanercept, and adalimumab has dramatically improved the outcome of severe RA beyond that achieved with traditional disease-modifying antirheumatic drugs (DMARDs) (11–13). This evidence concerns the gene TNF and rheumatoid arthritis.